Walden Biosciences

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.waldenbiosciences.com/

Last Round

Series A

Oct 6, 2020

Total Funding Raised

$51M

Company Overview

Walden Biosciences is a biotechnology company that develops targeted therapies for kidney diseases, including chronic kidney disease and acute kidney injury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologykidney diseasepodocyte healthdrug discoverymonoclonal antibodysmall molecule inhibitorclinical-stage biotechFSGSfocal segmental glomerulosclerosisdiabetic kidney diseaserenal therapynephrology biotechdrug pipelinebiopharmatherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Walden Biosciences Comparables

Compare Walden Biosciences with similar companies based on industry and business-model similarity.

Walden Biosciences comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Purespring Therapeutics	77%
Dimerix Ltd	76%
Novartis	71%

View all Comparables

Walden Biosciences Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Oct 6, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Blaine McKee

President And Chief Executive Officer

Executive Team

Diane Vrattos

Manager, Executive Office of President & CEO

Executive Team

Julie Morando

Manager, Executive Office of President and Chief Executive Officer

Executive Team

Curt Dewan

Chief Financial Officer

Executive Team

View all key people

Walden Biosciences Investors

Notable investors and investment history

Walden Biosciences investors
Investor	Rounds
UCB Ventures	Series A
ARCH Venture Partners	Series A
UCB Ventures	Series A
ARCH Venture Partners	Series A
ATEM Capital	Series A
Pandect Bioventures	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 28, 2025
Howard Mayer, M.D. appointed to the Board of Directors.

View all signals

Walden Biosciences Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Walden Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Walden Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts

Employee Range22

Year Founded2020

Last FundingOct 6, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.